A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease

Karthik Ananthasubramaniam, Robert Weiss, Bruce McNutt, Barbara Klauke, Kathleen Feaheny, Stan Bukofzer, Karthik Ananthasubramaniam, Robert Weiss, Bruce McNutt, Barbara Klauke, Kathleen Feaheny, Stan Bukofzer

Abstract

Background: The safety and tolerability of regadenoson, a pharmacologic stress agent that is excreted primarily by the kidneys, were examined in subjects with chronic kidney disease (CKD).

Methods: This multicenter, double-blind, randomized, placebo-controlled study involved men and women, ≥18 years of age, with stage 3 or 4 [estimated glomerular filtration rate (eGFR) 30-59 mL/minute/1.73 m(2) and 15-29 mL/minute/1.73 m(2), respectively] CKD and known or suspected coronary artery disease. Subjects were randomized 2:1 to receive one 10-second intravenous injection of regadenoson 0.4 mg or placebo. The primary outcome measure was the frequency of serious adverse events over 24-h post-dose.

Results: The study included 432 subjects with stage 3 (regadenoson n = 287; placebo n = 145) and 72 with stage 4 (regadenoson n = 47; placebo n = 25) CKD. No serious adverse events or deaths were reported over 24-h post-dose. The overall adverse event incidence was higher with regadenoson than placebo (62.6% vs 21.2%; P < .0001). Of the most common adverse events (≥5%) reported by subjects receiving regadenoson, headache (24.9% vs 7.1%), dyspnea (19.2% vs 0.6%), chest discomfort (14.7% vs 0.6%), nausea (14.7% vs 1.2%), flushing (12.0% vs 1.8%), and dizziness (9.6% vs 0.6%) occurred significantly more often (P < .0001) with regadenoson than placebo. There were no trends for clinically meaningful changes in eGFR from baseline to 24-h post-dose in subjects with stage 3 or 4 CKD.

Conclusions: Regadenoson was not associated with any serious or unexpected adverse events in subjects with stage 3 or 4 CKD.

Figures

Figure 1
Figure 1
Subject disposition
Figure 2
Figure 2
Mean (±SD) SBP, DBP, and HR following the administration of regadenoson or placebo

References

    1. Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology, and pharmacology. Am J Cardiol. 1997;79:2–10. doi: 10.1016/S0002-9149(97)00256-7.
    1. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527–552.
    1. Cerqueira MD. The future of pharmacologic stress: Selective A2A adenosine receptor agonists. Am J Cardiol. 2004;94:33D–40D. doi: 10.1016/j.amjcard.2004.04.017.
    1. Zablocki J, Palle V, Blackburn B, Elzein E, Nudelman G, Gothe S, et al. 2-substituted pi system derivatives of adenosine that are coronary vasodilators acting via the A2A adenosine receptor. Nucleosides Nucleotides Nucleic Acids. 2001;20:343–360. doi: 10.1081/NCN-100002306.
    1. Gao Z, Li Z, Baker SP, Lasley RD, Meyer S, Elzein E, et al. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: Inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther. 2001;298:209–218.
    1. Lexiscan® (regadenoson injection) [prescribing information]. Deerfield, IL: Astellas Pharma US Inc. April 2011.
    1. Buhr C, Gossl M, Erbel R, Eggebrecht H. Regadenoson in the detection of coronary artery disease. J Vasc Health Risk Manag. 2008;4:337–340.
    1. Hendel RC. Update on myocardial perfusion imaging: Role of regadenoson. Rep Med Imaging. 2009;2:13–23.
    1. Al Jaroudi W, Iskandrian AE. Regadenoson: A new myocardial stress agent. J Am Coll Cardiol. 2009;54:1123–1130. doi: 10.1016/j.jacc.2009.04.089.
    1. Garnock-Jones KP, Curran MP. Regadenoson. Am J Cardiovasc Drugs. 2010;10:65–71. doi: 10.2165/10489040-000000000-00000.
    1. Thompson CA. FDA approves pharmacologic stress agent. Am J Health Syst Pharm. 2008;65:890.
    1. Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol. 2007;47:825–833. doi: 10.1177/0091270007301620.
    1. Winter O, Veire N, Gemmel F, Goethals I, Sutter J. Myocardial perfusion imaging in the elderly: A review. Nucl Med Commun. 2006;27:529–534. doi: 10.1097/00006231-200606000-00009.
    1. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, Heijer M. Age- and gender-specific reference values of estimated GFR in Caucasians: The Nijmegen Biomedical Study. Kidney Int. 2007;72:632–637. doi: 10.1038/sj.ki.5002374.
    1. Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: Results from the Kidney Early Evaluation Program (KEEP) Am J Kidney Dis. 2010;55:S23–S33. doi: 10.1053/j.ajkd.2009.09.035.
    1. Leoncini G, Viazzi F, Rosei EA, Ambrosioni E, Costa FV, Leonetti G, et al. Chronic kidney disease in hypertension under specialist care: The I-DEMAND study. J Hypertens. 2010;28:156–162. doi: 10.1097/HJH.0b013e328332038c.
    1. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007;14:645–658. doi: 10.1016/j.nuclcard.2007.06.114.
    1. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, on behalf of the ADVANCE-MPI Trial Investigators Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging. J Am Coll Cardiol Imaging. 2008;1:307–316.
    1. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254.
    1. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470.
    1. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147.
    1. Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet. 2006;45:1201–1212. doi: 10.2165/00003088-200645120-00005.
    1. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005;353:2034–2041. doi: 10.1056/NEJMoa043104.
    1. Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, et al. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol. 2005;46:2069–2075. doi: 10.1016/j.jacc.2005.05.097.
    1. Lieu HD, Shryock JC, Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol. 2007;14:514–520. doi: 10.1016/j.nuclcard.2007.02.016.
    1. Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther. 2006;316:695–702. doi: 10.1124/jpet.105.095323.
    1. Zhang Y, Zhang L, Abraham S, Apparaju S, Wu TC, Strong JM, et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: Evaluation of recent new drug applications. Clin Pharmacol Ther. 2009;85:305–311. doi: 10.1038/clpt.2008.208.
    1. Cerqueira MD, Mahmarian JJ, Kinser C, Papatheofanis FJ, Segreti A. Frequency of aminophylline use to attenuate adverse reactions to regadenoson and adenosine. J Nucl Cardiol. 2009;16:658.
    1. Johnson SG, Peters S. Advances in pharmacologic stress agents: Focus on regadenoson. J Nucl Med Technol. 2010;38:163–171. doi: 10.2967/jnmt.109.065581.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する